Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


UPDATE: Ebos outlook subdued after Symbion boosts FY profit

UPDATE: Ebos outlook subdued after Symbion acquisition driven profit boost

(Adds investor comment, share price)

By Suze Metherell

Aug. 27 (BusinessDesk) - Ebos Group is unlikely to repeat a trebling of annual profit fuelled by last year acquisition of the Symbion pharmaceutical wholesaler and distributor in Australia, where regulatory changes are putting pressure on the sector.

The $1.1 billion cash and scrip Symbion purchase in June 2013 was a game-changer for the Christchurch-based healthcare and animal care manufacturer company, more than tripling annual revenue in a deal that gave Symbion’s owner Zuellig Group a cornerstone 40 percent stake in the New Zealand business. Net profit jumped to $92.1 million, or 62.8 cents a share, in the year ended June 30, its first full year after the acquisition, from $28.2 million, or 46.8 cents, a year earlier, it said in a statement, while sales soared 216 percent to $5.76 billion.

"It is pretty difficult to compare to the prior year because of that acquisition, which is a huge material uplift in their earnings," said Sam Trethewey, investment analyst at Milford Asset Management. "The big thing that really hurt them was the currency rate against the Australian dollar, that hurt their earnings when you translate it back into kiwi dollars. The result was in line, or slightly below what the market was expecting."

Australia now makes up 78 percent of sales and 80 percent of pretax earnings for the group. Changes to the country's Pharmaceutical Benefits Scheme has seen the Australian government reduce the number of drugs it funds, putting pressure on the drug retailing sector as a whole.

Ebos was coy on its outlook, saying while it faced "on-going regulatory challenges in our pharmacy markets we have always demonstrated innovative ways to generate earnings growth and we are confident that our management team can continue the company’s strong track record of growth into FY15."

Milford's Trethewey said it was unlikely 2015 would again see a trebling in profits but a falling New Zealand dollar against the Australian currency would support some growth, even as the Australian Federal government cuts to PBS funding in coming years squeezes margins for the pharmaceutical sector.

"It is a pretty subdued growth outlook for at least half their business," he said.

Ebos's healthcare segment's earnings before interest, tax, depreciation and amortisation rose 212 percent to $153 million, although the earnings margin slipped to 2.8 percent from 3 percent, while sales at the company's Australian pharmacy business were little changed from a year earlier. The company's animal care division reported a 100 percent jump in sales to $338.9 million and a 58 percent increase in Ebitda to $29.4 million, while the Ebitda/revenue margin shrank to 8.7 percent from 11 percent.

The company will pay a final dividend of 20.5 cents a share on Oct. 17, imputed at 35 percent. That takes payments for the year to 41 cents.

Shares of Ebos edged up 0.1 percent $9.46 in morning trading, and have slipped 2.6 percent this year while the benchmark NZX 50 Index rose 9.7 percent. The stock is rated a 'hold' based on the consensus of five analysts polled by Reuters, with a median price target of $10.29.

(BusinessDesk)

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Research: ‘Ageing Well’ Science Challenge Launched

Science and Innovation Minister Steven Joyce today launched the Ageing Well National Science Challenge, confirming initial funding of $14.6 million. More>>

ALSO:

Scoop Business: Govt Resisting Pressure To Pump More Cash Into Solid Energy

Prime Minister John Key says it is “not the government’s preferred option” to make a fresh capital injection into the troubled state-owned coal miner, Solid Energy, but dodged journalists’ questions at his weekly press conference on whether that might prove necessary... More>>

ALSO:

Lagest Ever Privacy Breach Award: NZCU Baywide Accepts “Severe” Censure In Cake Case

NZCU Baywide says that once it was found to have committed a breach of a former staff member’s privacy, it had attempted to resolve the matter... the censure and remedies for its actions taken almost three years ago are “severe” but accepted, and will hopefully draw a line under the matter. More>>

ALSO:

Scoop Business: PayPal Stops Processing Mega Payments; NZX Listing Still On

PayPal has ceased processing payments for Mega, the file storage and encryption firm looking to join the New Zealand stock market via a reverse listing of TRS Investments, amid claims it is not a legitimate cloud storage service. More>>

ALSO:

Housing Policy: Auckland Densification As Popular As Ebola, English Says

Finance Minister Bill English said calls by the Reserve Bank Governor for more densification in Auckland’s housing were “about as popular in parts of Auckland as Ebola” would be. More>>

ALSO:

Crown Accounts: NZ Government Deficit Smaller Than Expected In First Half

The New Zealand government's operating deficit was smaller than expected in the first six months of the financial year, as the consumption and corporate tax take rose ahead of forecast in December, having lagged estimates in previous months. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news